Speeches and presentations

Hal Barron, Chief Scientific Officer and President R&D, joined a virtual fireside chat hosted by Guggenheim analyst Seamus Fernandez at Guggenheim’s Biopharma Strategy Series.

The event, 'Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation' took place Tuesday, 29 June 2021 at 19:00 BST / 14:00 EDT, during which he provided an update on the progress GSK is making in R&D.

Emma Walmsley, CEO, and other members of CET hosted a virtual investor update at 14:00-17:30 BST on Wednesday 23 June. The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.

Brian McNamara, CEO, GSK Consumer Healthcare, presented at the conference and provided an introduction to GSK Consumer Healthcare and outlined our purpose, strategy, category-leading brands and capabilities, as well as an overview of the consumer healthcare sector.

Emma Walmsley, CEO, presented at CECP’s Biopharma Investor Forum on Tuesday 8 June at 8:40 EST/13:40 BST, during which she provided an overview on our approach to ESG. The presentation was followed by a moderated Q&A session.

Deborah Waterhouse, CEO of ViiV Healthcare, participated in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 10 at 8:35am ET/1:35pm GMT, during which she provided an update on the progress GSK is making in the HIV space.

Hal Barron, Chief Scientific Officer and President R&D, participated in a fireside chat at the Cowen 41st Annual Health Care Conference on Monday, March 1 2021 at 5:20pm GMT /12:20pm ET, during which he discussed updates on the progress GSK is making in R&D.

Axel Hoos, GSK Senior Vice-President Oncology R&D, joined a Fireside Chat with Seamus Fernandez at the Guggenheim Healthcare Talks 2021 Oncology Days, Thursday, February 11, at 10AM ET, where the duo discussed GSK Oncology R&D progress.

Hal Barron, Chief Scientific Officer and President R&D, presented at the 39th annual JP Morgan Virtual Healthcare Conference on Tuesday 12 January at 10:50-11:30am ET / 15:50-16:30 GMT.  The presentation was followed by a Q&A session. 

Emma Walmsley, CEO, hosted a fireside chat at the Goldman Sachs 13th annual healthcare unscripted CEOs conference on Tuesday 5 January at 12:00 GMT

Phil Thomson, President Global Affairs, hosted a fireside chat at the Morgan Stanley ESG Insights Conference on Wednesday, 9 December 2020 at 15:25 GMT / 10:25am EST.

Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at Evercore ISI HealthCONx Conference on Tuesday, 1 December 2020 at 13:00 GMT / 8:00am EST, during which provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.

GSK held an investor and analyst call hosted by Hal Barron, Chief Scientific Officer and President R&D, Roger Connor, President, GSK Vaccines, and Emmanuel Hanon, SVP and Head of Vaccines R&D, and discussed data on two respiratory syncytial virus (RSV) vaccine candidates to be presented at ID Week.

This event took place on Thursday 22 October at 3:30pm CET / 2:30pm BST / 9:30am EDT.

Emma Walmsley, CEO, hosted a fireside chat at the BofA Global Healthcare Conference on Thursday 17 September at 0815 BST.

Hal Barron, Chief Scientific Officer and President R&D, hosted a fireside chat at the Citi 15th Annual Biopharma Conference took place Wednesday 9 September 2020 at 16:40 BST/11:40am EDT, during which he provided an update on the progress GSK is making in the R&D pipeline.

GSK held an investor/analyst call hosted by David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO, ViiV Healthcare and Dr. Kimberly Smith, Head of R&D, ViiV Healthcare to discuss the final efficacy analysis from the global HIV Prevention Treatment Network (HPTN) 083 study evaluating investigational long-acting cabotegravir for HIV prevention.

This event took place on: Thursday 9 July at 14:00 BST / 09:00 EDT

Axel Hoos, Senior Vice-President Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum, Oncology Day, held in New York City on Thursday, February 13th, during which he provided an update on GSK Oncology R&D progress.

Emma Walmsley, CEO, presented at the 38th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 14 January, and provided an overview of GSK’s priorities and the progress the company made during 2019.  The presentation was followed by a Q&A session. 

On Tuesday, 17 December 2019 at 17:00 GMT / 12:00 EST, Hal Barron, Chief Scientific Officer and President of R&D, Luke Miels, President Pharmaceuticals and Axel Hoos, SVP Oncology R&D hosted an investor/analyst conference call to discuss GSK’s pivotal DREAMM-2 data on belantamab mafodotin (GSK’916).

On Monday, 30 September 2019, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of the PRIMA data on Zejula (niraparib) and the INDUCE-1 data on GSK’609 (ICOS) at the 2019 European Society for Medical Oncology (ESMO) congress. The call also featured participation from an external expert in ovarian cancer and other GSK senior oncology leaders.

Roger Connor, President, GSK Vaccines, hosted an educational session on GSK’s Vaccines business at our manufacturing site in Wavre, Belgium on Thursday 26 September at 13:30 CET / 12:30 BST / 7:30 EDT.

Hal Barron, Chief Scientific Officer and President R&D, hosted a fireside chat at Goldman Sachs’ 40^th Annual Global Healthcare Conference, which took place in Rancho Palos Verdes, California on Wednesday 12 June, during which he has provided an update on the progress being made in GSK’s R&D organisation.

David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, and Deborah Waterhouse, CEO of ViiV Healthcare, hosted a fireside chat at the Jefferies 2019 Healthcare Conference in New York on Thursday 6 June, during which they provided an update on the progress GSK and ViiV Healthcare have made this year.

Tobias Hestler, CFO GSK Consumer Healthcare, hosted a fireside chat at the Bernstein Consumer Healthcare & Nutrition Seminar in London on Tuesday 4 June during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

David Redfern, Chairman ViiV Healthcare, Deborah Waterhouse, CEO ViiV Healthcare and Dr Kimberly Smith, VP Global Research & Medical Strategy hosted a ViiV Healthcare analyst call on Tuesday 30 April to discuss ViiV Healthcare’s recent regulatory activities and provide an update on the pipeline.

Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at the Cowen & Co. 39th Annual Health Care Conference 2019 in Boston on Tuesday 12 March, during which he provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.

Brian McNamara, CEO GSK Consumer Healthcare, hosted a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference that took place in New York City on Thursday 28 February during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

Axel Hoos, SVP Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum - Oncology Day held in New York City on Thursday 14 February during which he provided an update on GSK Oncology R&D progress.

Emma Walmsley, CEO, gave a presentation at the 37th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 8 January, providing an overview of GSK’s priorities and the progress the company made during 2018.